Unbuzzd Clinical Trial Reports 40% Faster BAC Reduction and 67% Less Headache
Quantum BioPharma’s peer-reviewed trial found unbuzzd reduced blood alcohol concentration 40% faster within 30 minutes compared to placebo and sustained accelerated metabolism over four hours. Participants experienced 67% less headache severity at four hours, improved alertness, stabilized vital signs and no adverse effects in the double-blind crossover study.
1. Clinical Trial Overview
Quantum BioPharma completed a double-blind, randomized, placebo-controlled crossover clinical trial (NCT06505239) involving healthy male and female participants aged 21–43 weighing between 119 and 232 pounds. Participants consumed measured alcohol to reach a 0.07–0.11% BAC then ingested either unbuzzd or placebo, with BAC, vital signs and intoxication symptoms monitored over four hours.
2. Accelerated Alcohol Metabolism
unbuzzd accelerated blood alcohol reduction by more than 40% within the first 30 minutes versus placebo, with continued significant acceleration at each subsequent measurement through four hours. This rapid metabolism effect was observed consistently across gender groups.
3. Cognitive and Physiological Benefits
Study subjects reported marked improvements in alertness and made fewer cognitive errors within 30 minutes of unbuzzd ingestion. The supplement also stabilized heart rate and blood pressure and delivered a 67% reduction in headache severity at four hours, with sustained symptom relief at eight hours.
4. Safety and Availability
unbuzzd was well tolerated with no reported adverse effects during the trial. The proprietary formula is licensed to Unbuzzd Wellness Inc. and is commercially available in powder stick form via the company website and Amazon.